PET-guided, BEACOPP
escalated
therapy in advanced Hodgkin lymphoma - Authors' reply
Lancet Oncol
.
2019 Apr;20(4):e190.
doi: 10.1016/S1470-2045(19)30156-1.
Authors
René-Olivier Casasnovas
1
,
Reda Bouabdallah
2
,
Pauline Brice
3
,
Julien Lazarovici
4
,
Hervé Ghesquieres
5
,
Aspasia Stamatoullas
6
,
Alina Berriolo-Riedinger
7
,
Luc-Matthieu Fornecker
8
,
Marc André
9
,
Michel Meignan
10
Affiliations
1
Department of Hematology, University Hospital F Mitterrand and Inserm UMR 1231, Dijon 21000, France. Electronic address:
[email protected]
.
2
Department of Hematology, Institut P Calmette, Marseille, France.
3
Department of Hematology, APHP, Hopital Saint Louis, Université Paris Diderot, Paris, France.
4
Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
5
Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud and Université Claude Bernard Lyon-1, Pierre Bénite, France.
6
Department of Hematology, Centre H Becquerel, Rouen, France.
7
Department of Nuclear Medicine, Centre G F Leclerc, Dijon, France.
8
Department of Hematology, University Hospital of Strasbourg, Strasbourg, France.
9
Department of Hematology, CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium.
10
LYSA Imaging, University Hospital H Mondor, Creteil, France.
PMID:
30942177
DOI:
10.1016/S1470-2045(19)30156-1
No abstract available
Publication types
Letter
Comment
MeSH terms
Cyclophosphamide
Hodgkin Disease*
Humans
Positron-Emission Tomography
Procarbazine
Vincristine
Substances
Procarbazine
Vincristine
Cyclophosphamide